RxDoctor Payments DataLook up a doctor →

Albert Marano, MD

Neurology · Johnston, RINPI 1336290311

Payments from drug & device makers

$145,271in general payments, 2019–2025

Across 2,586 payments — averaging $56.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$29K
  • AbbVie$25K
  • Genentech USA, Inc.$20K
  • Biohaven Pharmaceuticals, Inc.$13K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • plus $42K from 54 others

What the payments were for

  • Speaking & faculty fees$98,37268%
  • Travel & lodging$4460%
  • Food & beverage$46,09032%
  • Education$3630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.132$28,940
AbbVie(2 entities)248$24,854
Genentech USA, Inc.63$20,068
Biohaven Pharmaceuticals, Inc.54$12,979
E.r. Squibb & Sons, L.L.C.15$8,463
Biohaven Pharmaceutical Holding Company Ltd.19$7,329
Pfizer81$4,591
Bristol Myers Squibb41$4,204
Lundbeck LLC99$2,467
Biogen131$2,271
Teva Pharmaceuticals USA, Inc.267$2,089
Novartis139$1,902
EMD Serono, Inc.69$1,845
UCB, Inc.84$1,812
Amgen(2 entities)77$1,589
Neurocrine Biosciences, Inc.74$1,365
Neurelis, Inc.41$1,205
Takeda Pharmaceuticals U.S.A., Inc.94$1,177
Eisai Inc.55$1,127
Acadia Pharmaceuticals Inc70$910
Mallinckrodt Hospital Products Inc.26$727
CSL Behring39$717
Kyowa Kirin, Inc.35$700
Axsome Therapeutics, Inc.27$695
Lilly USA, LLC32$668
MDD US Operations, LLC19$565
Jazz Pharmaceuticals Inc.19$553
Acorda Therapeutics, Inc37$522
Xeris Pharmaceuticals, Inc.34$489
Sunovion Pharmaceuticals Inc.46$488
AstraZeneca(2 entities)23$460
Adamas Pharmaceuticals, Inc.27$443
Catalyst Pharmaceuticals, Inc.22$432
Mallinckrodt Enterprises LLC16$414
Livanova USA, Inc.8$399
Supernus Pharmaceuticals, Inc.34$399
TG Therapeutics, Inc.15$379
Amneal Pharmaceuticals LLC29$373
Upsher-smith Laboratories LLC19$357
Avadel CNS Pharmaceuticals, LLC12$355
Johnson & Johnson(2 entities)10$334
Harmony Biosciences LLC11$329
Otsuka America Pharmaceutical, Inc.16$311
Avanir Pharmaceuticals, Inc.20$297
Grifols USA, LLC16$260
Merz North America, Inc.12$216
Sanofi9$183
Assertio Therapeutics, Inc.13$177
Amylyx Pharmaceuticals, Inc.6$173
Vanda Pharmaceuticals Inc.7$166
GE HealthCare22$142
Shire North American Group Inc9$138
Arbor Pharmaceuticals, Inc.6$123
Akcea Therapeutics, Inc.6$117
Ipsen Biopharmaceuticals, Inc5$107
Avion Pharmaceuticals5$101
Strongbridge US Inc.6$88
Sumitomo Pharma America, Inc.3$71
Promius Pharma LLC3$68
Almatica Pharma LLC3$63

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,271 in reported general payments places this provider in the 90th percentile of 86 neurology providers in Rhode Island.

See all neurology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$101,967
Medicare patients
344
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b13$146,879
BotoxOnabotulinumtoxina117$132,995
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$130,960
IngrezzaValbenazine Tosylate16$126,305
EpidiolexCannabidiol (Cbd)14$78,879
NuplazidPimavanserin Tartrate16$77,011
XcopriCenobamate47$57,310
Emgality PenGalcanezumab-Gnlm52$38,005
RytaryCarbidopa/Levodopa29$36,067
Nurtec OdtRimegepant Sulfate19$35,607
UbrelvyUbrogepant28$32,030
QuliptaAtogepant19$20,501
Lacosamide208$19,456
RexultiBrexpiprazole13$18,434
NuedextaDextromethorphan Hbr/Quinidine11$16,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta, Savella$24,854$191,526176 claims
CSL BehringPrivigen$717$130,96013 claims
Neurocrine Biosciences, Inc.Ingrezza$1,365$126,30516 claims
Acadia Pharmaceuticals IncNuplazid$910$77,01116 claims
SK Life Science, Inc.Xcopri$28,940$57,31047 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$373$37,88040 claims
PfizerNurtec Odt, Dilantin$4,591$37,37631 claims
Otsuka America Pharmaceutical, Inc.Rexulti$311$18,43413 claims
Avanir Pharmaceuticals, Inc.Nuedexta$297$16,20211 claims
Arbor Pharmaceuticals, Inc.Horizant$123$11,58312 claims
Ipsen Biopharmaceuticals, IncDysport$107$5,52311 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,177$4,98811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 86 neurology providers in Rhode Island.

Other neurology in Johnston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →